KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · IEX Real-Time Price · USD
10.77
+0.28 (2.67%)
Apr 26, 2024, 3:18 PM EDT - Market open
Company Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States.
The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE.
The company is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Benjamin L. Palleiko |
Contact Details
Address: 55 Cambridge Parkway, Suite 901e Cambridge, Massachusetts 02142 United States | |
| Phone | (857) 999-0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| Employer ID | 20-0915291 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Edward P. Feener Ph.D. | Chief Scientific Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Michael D. Smith Pharm.D. | Senior Vice President of Development |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Nicole Sweeny | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 10-Q | Quarterly Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 424B5 | Filing |